T cells engineered with T-cell antigen coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity

      Engineering T cells with chimeric antigen receptors (CARs) is an effective method for directing T cells against tumors in an MHC-independent manner. CARs trigger T cell signaling by combining functional components of the TCR and co-stimulatory molecules. We designed an alternate chimeric receptor that retains MHC-independent antigen recognition but signals through the native TCR. Our novel chimeric receptor, named the T-cell Antigen coupler (TAC), is membrane-anchored, co-opting the TCR and co-receptor in the presence of tumor antigen.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect